Jin Shi, Hu Weina
Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Department of Cardiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Front Endocrinol (Lausanne). 2021 Apr 30;12:602735. doi: 10.3389/fendo.2021.602735. eCollection 2021.
Coronavirus disease 2019 (COVID-19), which was named by the World Health Organization (WHO) in February 2020, has quickly spread to more than 200 countries around the world and was declared as a global pandemic in March 2020. The severity of the disease makes it more prone to severe symptoms and higher mortality rates in patients, especially those who are with comorbidities, including high blood pressure, cardiovascular disease, obesity, and diabetes, increases the concern over the consequences of this pandemic. However, initial reports do not clearly describe whether diabetes itself or associated comorbidities or treatment strategies contribute to the severe prognosis of COVID-19 infections. Various clinical trials are being conducted on glucose-lowering agents but to date, there is no standard treatment protocol approved for COVID-19 cases with pre-existing diabetes. This review is aimed to decipher the potential risk factors of COVID-19 involved from existing evidence. Identification of a novel therapeutic strategy could be beneficial for combating SARS-CoV-2, which might be dreadful to debilitating people who have diabetes.
2019冠状病毒病（COVID-19）于2020年2月由世界卫生组织（WHO）命名，迅速蔓延至全球200多个国家，并于2020年3月被宣布为全球大流行。该疾病的严重性使其在患者中更容易出现严重症状和更高的死亡率，尤其是那些患有包括高血压、心血管疾病、肥胖症和糖尿病在内的合并症的患者，这增加了人们对这场大流行后果的担忧。然而，初步报告并未明确描述是糖尿病本身、相关合并症还是治疗策略导致了COVID-19感染的严重预后。目前正在对降糖药物进行各种临床试验，但迄今为止，尚无针对已有糖尿病的COVID-19病例批准的标准治疗方案。本综述旨在从现有证据中解读COVID-19的潜在风险因素。确定一种新的治疗策略可能有助于对抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2），这对患有糖尿病的虚弱人群可能是可怕的。
